Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In Re Copaxone 40 MG Consolidated Cases
Case Number:
1:14-cv-01171
Court:
Nature of Suit:
Judge:
Firms
- Duane Morris
- Gould & Ratner
- Heyman Enerio
- Phillips McLaughlin
- Richards Layton
- Shaw Keller
- Smith Katzenstein
- Young Conaway
Companies
- Amneal Pharmaceuticals Inc.
- Momenta Pharmaceuticals Inc.
- Pfizer Inc.
- Sandoz International GmbH
- Synthon International Holding B.V.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
Sectors & Industries:
-
February 21, 2017
FDA Warning Wire: Pfizer Lapse Boosts Teva Blockbuster
A newly disclosed warning letter to Pfizer is setting off a chain reaction that will likely delay a generic version of Teva's blockbuster Copaxone, one of the world's best-selling drugs. Here's a look at the remarkable development and other U.S. Food and Drug Administration warnings announced in recent days.
-
January 31, 2017
Teva Vows Appeal After 4 Copaxone Patents Invalidated
A Delaware federal judge sided Monday with generic-drug makers including Sandoz, Mylan and Pfizer and invalidated four patents for Teva's multiple sclerosis drug Copaxone they were accused of infringing.